Skip to the sheet
GLP1Rx workbook

Coverage, cash pay, and the path from a visit to a filled prescription.

Workbook sheet

Manufacturer savings offers and who they exclude

GLP1Rx.org editorial team. Published November 18, 2026. Last reviewed November 18, 2026.

A savings offer is a manufacturer discount with a rulebook. It is not insurance, and the companies say so on the pages. The number in an advertisement is the best case for a person who meets every condition, not the price a pharmacy must charge you. This sheet records what those pages said when reviewed on November 18, 2026. Recheck them. Offers end. The live comparison site cheapestglp1withoutinsurance.com is a better place to watch movement than a printed table. Which product the offer applies to is a label question. The semaglutide monograph keeps Wegovy, Ozempic, and Rybelsus from sharing one discount by accident.

The exclusion that changes the ad

NovoCare’s Wegovy savings language says eligible commercially insured patients may pay as little as $25, subject to a maximum savings of $100 per month. Government beneficiaries are excluded. Lilly’s Zepbound single-dose pen language, the insurance price of as little as $25 per month, likewise says governmental beneficiaries are excluded. Lilly’s page names examples: Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, Department of Defense, VA, TRICARE, and state prescription-drug assistance programs.

If you have any of those cards, do not budget the $25 line. A pharmacy that runs the card and then reverses it is not overcharging you relative to the offer. The offer never applied. Medicare beneficiaries looking at weight-management coverage should read the prior authorization sheet, which summarizes the GLP-1 Bridge CMS described, including a $50 copay figure that is a demonstration rule, not the NovoCare card.

Wegovy figures published by NovoCare

List price, from the NovoCare page that explains list price for Wegovy: $1,349.02 per package. That is the posted price before discounts. It is not the self-pay offer.

Self-pay for the pen, from the patient page, the savings-offer page, and the price-guide PDF reviewed the same day: a standard price of $349 for a 28-day supply, defined as one box of four pens, at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Wegovy HD 7.2 mg was listed at $399 per 28-day supply. Patients new to the savings offer or to NovoCare home delivery were described as paying $199 for each of the first two monthly fills of 0.25 mg and 0.5 mg, through an offer dated to December 31, 2026, then the $349 standard price. Multi-month fills at the standard price were shown in the delivery terms as multiples, for example $698 and $1,047 for two and three months at the $349 doses. The PDF says pricing can be for local pharmacy pickup with a savings offer or for home delivery, with exceptions, and that Novo Nordisk can modify or cancel the program.

Self-pay for Wegovy tablets, from the same pages: $149 per month of 1.5 mg, $199 per month of 4 mg, and $299 per month of 9 mg and 25 mg. A month is one bottle of 30 tablets. The empty-stomach dosing of those tablets is a label issue, not a coupon issue. Do not split tablets to make the cheaper strength last longer. The label says swallow them whole.

To get the self-pay prices, NovoCare says the prescription is filled through NovoCare home delivery or with the savings offer at the pharmacy. The offer is not combined, on the terms reviewed, with unrelated coupons. Cash at a random counter, with no offer on file, can land on a price closer to the list price. Ask the pharmacy which price it is about to bill before you nod.

Zepbound figures published by LillyDirect

Reviewed the same day, LillyDirect’s Zepbound page listed a self-pay price for the 2.5 mg KwikPen starting at $299 per month. A month for the KwikPen is 28 days and one pen. The 2.5 mg dose is a starting dose, and Lilly’s page repeats that it is not a maintenance dose. For 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the page listed a price starting at $449 per month when refilled within 45 days under the Journey Program. If that window is missed, the footnote listed regular prices of $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. The 5 mg self-pay price is dose-specific on the live page. This sheet does not invent a dollar amount for 5 mg that we could not read unambiguously. Check the page for that strength before you compare it with Wegovy’s flat $349 pen price.

Single-dose vials at 10 mg, 12.5 mg, and 15 mg followed the same “starting at $449 when refilled within 45 days” pattern, with a month defined as four vials, and the page says a needle and syringe are a separate purchase. The single-dose pen was presented as an insurance path, as low as $25, governmental beneficiaries excluded, not as the self-pay vial price. Lilly says terms can be terminated or changed and that the program is not insurance. Savings may be applied automatically through LillyDirect. Filling at another pharmacy may require a different savings route. The page also points Medicare Part D patients with a KwikPen prescription for weight management toward the Medicare GLP-1 Bridge rather than toward the commercial $25 card.

What an offer does not discount

It does not discount a compounded vial. Manufacturer pages reviewed here are about Wegovy and Zepbound presentations those companies sell. A telehealth membership that includes “semaglutide” at $199 may be selling a compounded product, a visit, or both. Ask. It does not pay your prescriber. A drug offer plus a visit fee is the real monthly cost. It does not override a plan exclusion. If the plan pays nothing and you are commercially insured, you may still use a self-pay path if the terms allow insured patients to opt out and pay cash. NovoCare’s delivery terms, as reviewed, have said patients may be uninsured or insured and choosing to self-pay, for an FDA-approved indication. Read the current terms. Do not assume last year’s checkbox.

It does not make two GLP-1 drugs a good idea. Labels say not to combine them. A savings card on a second product is not a clinical rationale.

How to use the offer without getting surprised

  1. Confirm the product and strength on the prescription match a row the manufacturer actually prices.
  2. Confirm you are not a government beneficiary if you are counting on the $25 commercial offer.
  3. Ask whether the pharmacy has the offer on file, or whether you must use the manufacturer’s pharmacy.
  4. Ask what happens at the next strength. A starter price on 0.25 mg is not always the price of 2.4 mg, except where the page explicitly flattens them, as NovoCare did for the standard pen doses from 0.25 through 2.4 mg at $349.
  5. Put the date you checked on your own note. This sheet’s date is November 18, 2026.

Keep the paperwork that proves which price you were charged. A receipt that says “Wegovy” and a dollar amount, dated, is what you compare with the manufacturer page if the pharmacy later says the offer was exhausted. If the receipt is far above both the self-pay figure and the list price, ask for the billed national drug code and the quantity. A 28-day box billed as something else is a different problem from a lapsed coupon. Pharmacies can correct a misapplied offer more easily in the same week than three months later. None of that detective work applies to a compounded product the manufacturer never discounted, which is why the product name has to be settled before the coupon conversation starts.

Cash prices lines these figures up next to list price. If coverage is denied is the sheet for when the plan, not the coupon, is the problem. Neither sheet is a promise that the offer will still be posted next month.

Sources checked for this sheet

  1. https://www.novocare.com/patient/medicines/wegovy.html
  2. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  3. https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
  4. https://www.lilly.com/lillydirect/zepbound
  5. https://www.novocare.com/mash/resources/explaining-list-price.html
  6. https://cheapestglp1withoutinsurance.com/
  7. https://glp1meds.org/monographs/semaglutide